Elaine Kingwell
Overview
Explore the profile of Elaine Kingwell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang Y, Cesta C, Liu Q, Kingwell E, Stridh P, Shchetynsky K, et al.
Mult Scler
. 2024 Nov;
30(14):1765-1774.
PMID: 39503308
Background: Women have a higher risk of developing multiple sclerosis (MS), potentially due to hormonal factors. Elevated testosterone levels, common in polycystic ovary syndrome (PCOS), might influence MS risk. Objective:...
2.
McKay K, Wijnands J, Manouchehrinia A, Zhu F, Sereda P, Li J, et al.
Ann Neurol
. 2023 Dec;
95(3):487-494.
PMID: 38098141
Objective: There has been interest in a possible negative association between HIV and multiple sclerosis (MS). We aimed to compare the risk of MS in a cohort of individuals living...
3.
Fedeli U, Barbiellini Amidei C, Avossa F, Schievano E, Kingwell E
Eur J Neurol
. 2023 Jun;
30(9):2870-2873.
PMID: 37306563
Background And Purpose: People with multiple sclerosis (MS) suffer from higher infection-related mortality compared to the general population; however, sparse data are available on the increased risk of death associated...
4.
Yusuf F, Wijnands J, Karim M, Kingwell E, Zhu F, Evans C, et al.
Front Neurol
. 2022 Nov;
13:1017492.
PMID: 36408518
Background And Objectives: Little is known of the potential sex and age differences in the MS prodrome. We investigated sex and age differences in healthcare utilization during the MS prodrome....
5.
Ng H, Zhu F, Kingwell E, Yao S, Ekuma O, Evans C, et al.
Neurol Neuroimmunol Neuroinflamm
. 2022 Jun;
9(5).
PMID: 35701187
Background And Objectives: We examined the association between the disease-modifying drugs (DMDs) for multiple sclerosis (MS) and survival in a multiregion population-based study. Methods: We accessed multiple administrative health databases...
6.
Ng H, Graf J, Zhu F, Kingwell E, Aktas O, Albrecht P, et al.
Front Immunol
. 2022 Jan;
12:794075.
PMID: 35095869
Background: Evidence regarding the efficacy or effectiveness of the disease-modifying drugs (DMDs) in the older multiple sclerosis (MS) population is scarce. This has contributed to a lack of evidence-based treatment...
7.
Ng H, Zhu F, Kingwell E, Zhao Y, Yao S, Ekuma O, et al.
Mult Scler
. 2021 Dec;
28(4):583-596.
PMID: 34949130
Objective: We assessed the relationship between the multiple sclerosis (MS) disease-modifying drugs (DMDs) and healthcare use. Methods: Persons with MS (aged ⩾18 years) were identified using linked population-based health administrative...
8.
McKay K, Tremlett H, Zhu F, Kastrukoff L, Marrie R, Kingwell E
Int J Popul Data Sci
. 2021 Aug;
1(1):28.
PMID: 34381875
No abstract available.
9.
Roux J, Kingwell E, Zhu F, Tremlett H, Leray E
Mult Scler
. 2021 May;
28(2):309-322.
PMID: 34048293
Background: Persons with multiple sclerosis (PwMS) typically require complex multidisciplinary care, which is rarely formally assessed. Objectives: We applied multichannel sequence analysis (MCSA) to identify care consumption patterns by PwMS...
10.
Evans C, Marrie R, Yao S, Zhu F, Walld R, Tremlett H, et al.
BMJ Open
. 2021 Feb;
11(2):e043930.
PMID: 33550262
Objective: To determine whether better medication adherence in multiple sclerosis (MS) might be due to specialised disease-modifying drug (DMD) support programmes by: (1) establishing higher adherence in MS than in...